Inhibitor Program News Today

Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.

/PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its...

- Phase 2 CSU enrollment complete; topline data by YE 2023 -

SOUTH SAN FRANCISCO, Calif., June 21, 2023 -- Assembly Biosciences, Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today... | June 21, 2023

Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program CSF-1R inhibitors show promising anti-tumor activityLead compound shows...

Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program CSF-1R inhibitors show promising anti-tumor activityLead compound shows synergy with PD1 cancer immune checkpoint... | June 15, 2023

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual... | June 9, 2023

08.05.2023 - Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) - Prelude Therapeutics Incorporated (Nasdaq: ...

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline ... | May 8, 2023

Cold urticaria and symptomatic dermographism . These randomized, double-blind, placebo-controlled, parallel group Phase 2 studies are evaluating the efficacy and safety profile of multiple dose... | May 4, 2023